In pancreas cancer patients with a germline BRCA mutation, olaparib provided a progression-free survival benefit but did not improve overall survival compared to placebo.

“if you have a bracket germline mutation in pancreas cancer they did a randomized trial where they gave people four months of the standard of care full fearing ox therapy and they stopped it after a minimum of four months you could have had a little bit more but they stopped it after four months and randomized you to a lap rib or sugar pill and if you take olap rib you have a progression-free survival benefit which i can explain what it is in a second versus sugar pale but you don't have an overall survival benefit you're not living any longer”